TY -的T1 SARS-CoV-2临床,随着破坏ch: the role of a rare disease-specific trial network JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02114-2020 VL - 56 IS - 3 SP - 2002114 AU - van Koningsbruggen-Rietschel, Silke AU - Dunlevy, Fiona AU - Bulteel, Veerle AU - Downey, Damian G. AU - Dupont, Lieven Y1 - 2020/09/01 UR - //www.qdcxjkg.com/content/56/3/2002114.abstract N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has disrupted clinical trials worldwide [1]. This could delay the approval of new medicines and reduce access to investigational treatments via clinical trials. This particularly impacts patients with rare diseases such as cystic fibrosis (CF).Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. https://bit.ly/3hCw5dq ER -